Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

INTRODUCTION: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should theref...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Sidana, Surbhi, Narkhede, Mayur, Elson, Paul, Hastings, Debbie, Faiman, Beth, Valent, Jason, Samaras, Christy, Hamilton, Kimberly, Liu, Hien K., Smith, Mitchell R., Reu, Frederic J.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344345/
https://ncbi.nlm.nih.gov/pubmed/28278302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0172996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados